The 2023-2028 World Outlook for Analyzers and Test Kits

The 2023-2028 World Outlook for Analyzers and Test Kits

This study covers the world outlook for analyzers and test kits across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

In this report we define the sales of analyzers and test kits as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott, AbbVie, AES laboratoire, Affymetrix, Agilent, Alere, American Diabetes Association, Argene, Axis-Shield, PLC, Beckman Coulter, bioMérieux, BioReliance, Biotech Fund Flanders, Cardiovascular Care, Centre for Devices and Radiological Health (CDRH), Danaher, DePuy, DiaSorin, eBioscience, Ernst and Young, eScreen, Ethicon Endosurgery, Eucomed, European Diagnostics Manufacturers Association (EDMA), Food and Drug Administration (FDA) US, Fujirebio Diagnostics, Gifu University, Gimv, Goldman Sachs, Health Protection Agency (HPA), Hycor-Agilent, Inova Diagnostics, Iris Healthcare, Italian National Health Service, J Mitra & Company, Lilac Medicare, Lyon Civil Hospitals, MedSciences Capital (MSC), Merieux Institute, MP Healthcare Venture Management (MPH), National Health Service (NHS), Ortho Clinical Diagnostics, Phadia, Pharmaceutical and Medical Devices Agency (PMDA) Japan, Philips Electronics, Price Waterhouse Coopers (PWC), Pronota, QUALIGEN, Roche, Shenzhen Mindray Bio-Medical Electronics Company, Siemens, Sigma- Aldrich, Span Diagnostics, State Food and Drug Administration, Substance Abuse and Mental Health Services Administration (SAMHSA), Suyog Diagnostics, Sysmex, The Carlyle Group, Transasia, Tulip Diagnostics, United Nations, US National Library of Medicine (NLM), Valeritas, Vision Care, and World Health Organization (WHO). In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).